2025
Frankenfeld CL , Movva N , Reichert H , Doepker C. Dietary intake and nutrient adequacy differ across GLP-1RA users based on length of GLP1-RA use. Poster 268, ObesityWeek 2025, Atlanta, GA, November 5, 2025.
View Abstract
Publication: Abstracts and Presentations
2024
Davison NJ, Guthrie NL, Medland S, Lupinacci P, Nordyke RJ , Berman MA. 2024. Cost-effectiveness analysis of a prescription digital therapeutic in Type 2 diabetes. Adv Ther 41(2):806-825; doi: 10.1007/s12325-023-02752-2 . PMID: 38170435.
View Abstract
Publication: Manuscripts
2022
Klosterbuer A, Cekola P, Neutel JM, Jiang X , Cohen SS, Torres KA. Diabetes specific ONS led to a blunted postprandial glucose response and a 26% reduction in peak blood glucose levels compared to a standard ONS. Presented at FNCE 2022 Food & Nutrition Conference & Expo, Orlando, FL, October 2022.
Publication: Abstracts and Presentations
2019
Nordyke RJ , Appelbaum K, Berman MA. 2019. Estimating the impact of novel digital therapeutics in Type 2 diabetes and hypertension: Health economic analysis. J Med Internet Res 21(10):e15814; doi: 10.2196/15814 . PMID: 31937249.
View Abstract
Publication: Manuscripts
2018
Ludden T, Ermakova A, Xiong Y, Cyr PL , Sieradzan R, Sacks NC , Taylor SD. Comparison of healthcare resource utilization for multiple-daily injections (MDI) with basal and bolus insulin therapy versus non-MDI therapy in patients with Type 2 diabetes. Poster presentation at Academy of Managed Care Pharmacy Annual Research Meetings, Boston, MA, 2018.
Publication: Abstracts and Presentations
Ludden T, Ermakova A, Xiong Y, Cyr PL , Sieradzan R, Sacks NC , Taylor SD. Comparison of healthcare resource utilization and clinical status among Type 2 diabetes patients using multiple-daily injection (MDI) insulin therapy vs. non-MDI therapy. ISPOR 23rd Annual Conference, Baltimore MD, 2018.
A Division of